Have you been diagnosed with non-clear cell RCC? Clinical trials are an excellent way for patients to access new treatments for rare subtypes. This chart lists all active and enrolling clinical trials for non-clear cell RCC.
Click on the NCI Trial ID to learn more about each non-clear cell RCC trial including eligibility criteria and information about enrollment. Listing a study is not an endorsement of any clinical trial.
Connect with other patients who have been diagnosed with a subtype of kidney cancer other than clear cell by joining a KCCure community today.
If you have information about non-clear cell clinical trials or would like to suggest an addition or change, contact Info@kccure.org.
| NCI Trial ID | Histology | Treatment | Phase | Locations |
|---|---|---|---|---|
| NCT05678673 | Papillary, unclassified (NOS), MIT family translocation | XL092 + nivolumab vs. sunitinib | III | 6 states in the U.S., open at locations in Europe, South America, Australia and Asia |
| NCT06053658 | Non-clear Cell RCC - excluding RMC and collecting duct | Tivozanib + nivolumab | II | Houston, TX |
| NCT05043090 | MET driven Papillary RCC | Salvolitinib + Durvalumab vs. sunitinib or durvalumab monotherapy | III | 3 states in the U.S., open at locations in Europe, South America, Australia, and Asia |
| NCT04071223 | Non-Clear Cell & Clear Cell RCC with metastatic bone disease | Cabozantinib + Radium 223 | II | Open throughout the U.S. |
| NCT05411081 | Papillary | Cabozantinib compared to Cabo + atezolizumab | II | Available throughout U.S. |
| NCT04981509 | HLRCC, or papillary RCC | bevacizumab + erlotinib + atezolizumab | II | GA, IL, MD, NJ, OH, PA |
| NCT05665361 | Papillary RCC | Palbociclib + sasalimab | I/II | Bethesda, MD (NIH) |
| NCT05620134 | Papillary RCC | JK08 (IL15 antibody fusion protein targeting CTLA4) | I/II | Belgium, Spain |
| NCT05752552 | MET driven disease, hereditary renal papillary RCC | DO2 - deuterated MET kinase inhibitor | I | Belgium, Netherlands, France |
| NCT03866382 | Papillary RCC, Chromophobe RCC, Sarcomatoid RCC and Renal Medullary Carcinoma | [Nivolumab + ipilimumab + cabozantinib] (combination immunotherapy and targeted therapy) | II | ID, MT, NE, OR, WY |
| NCT06302569 *opening soon | Renal Medullary Carcinoma or Collecting Duct | Enfortumab Vedotin (EV) + pembrolizumab | II | Italy |
| NCT05347212 | Renal Medullary Carcinoma (RMC) | nivolumab + relatimab | II | Houston, TX |
| NCT06161532 | Renal Medullary Carcinoma | Sacituzumab govitecan +/- atezolizumab | II | Bethesda, MD (NIH) |
| NCT05286801 | Renal Medullary Carcinoma and other tumors with loss of SMARCB1 or SMARCA4 | tiragolumab and atezolizumab | II | 22 states in the U.S., Australia, and Canada |
| NCT03715933 | SDH-deficient tumors | Tetravalent (DR5 agonist antibody) + temozolomide | I | Enrolling in 14 states throughout the U.S. |
| NCT04250155 | Open to all solid tumors - may have relevance for Chromophobe | Arm 1: XmAb24306 (IL-15 agonist) as a single agent. Arm 2: XmAb23406 in combination with PD-L1 inhibitor atezolizumab | I | Enrolling in 5 states, Canada, Australia, Europe, South America, and Asia |
| NCT03388632 | Open to all solid tumors - may have relevance for Chromophobe | Arm 1: IL-15 in combination with nivolumab (Opdivo) Arm 2: IL-15 in combination with ipilimumab (Yervoy) Arm 3: IL-15 in combination with nivolumab and ipilimumab | I | NIH Bethesda |